SCHEDULE 13G/A: FMR LLC and Abigail P. Johnson Disclose 7.9% Passive Stake in Dyne Therapeutics Inc.

FMR LLC and Abigail P. Johnson have filed an amended Schedule 13G, reporting a 7.9% beneficial ownership stake in Dyne Therapeutics Inc. as of December 31, 2024.

Summary

• FMR LLC and Abigail P. Johnson reported beneficial ownership of 7,996,931 shares of Dyne Therapeutics Inc. common stock.
• This ownership represents 7.9% of the company's total outstanding common stock.
• FMR LLC holds sole voting power over 7,995,592 shares and sole dispositive power over 7,996,931 shares.
• Abigail P. Johnson, as a Director, Chairman, and Chief Executive Officer of FMR LLC, is also deemed to beneficially own these shares due to her control over FMR LLC.
• The shares were acquired and are held in the ordinary course of business and not for the purpose of changing or influencing the control of Dyne Therapeutics Inc.
• The filing is an Amendment No. 1 to a Schedule 13G, updating previously reported beneficial ownership information.

Sentiment

Score: 5

Explanation: The filing is a routine regulatory disclosure of beneficial ownership and does not contain information that would significantly alter the company's fundamental outlook. The presence of a significant institutional investor stake can be viewed as a neutral to slightly positive signal.

Positives

• The disclosure confirms a significant 7.9% beneficial ownership stake by FMR LLC, a major institutional investor, in Dyne Therapeutics Inc.
• The investment is stated to be for the ordinary course of business, indicating a passive, long-term investment approach rather than an activist one.

Negatives

• The document does not contain information that would be considered negative.

Risks

• The document, being a beneficial ownership statement, does not detail specific operational or financial risks related to Dyne Therapeutics Inc.

Future Outlook

The document, a Schedule 13G filing, does not provide any forward-looking statements or guidance regarding Dyne Therapeutics Inc.'s future outlook.

Industry Context

This Schedule 13G filing is a routine disclosure of beneficial ownership by a major institutional investor and does not provide specific industry context or trends.

Stakeholder Impact

• Shareholders: Provides transparency regarding significant institutional ownership, which can be viewed as a vote of confidence by a major financial entity.

Key Dates

Keywords

Dyne Therapeutics Inc., FMR LLC, Abigail P. Johnson, Schedule 13G, Beneficial Ownership, Common Stock, Institutional Investor